User:Mr. Ibrahem/Lumasiran

Lumasiran, sold under the brand name Oxlumo, is a medication used to treat primary hyperoxaluria type 1 (PH1). It lowers both urine and blood oxalate level. It is given by injection under the skin.

Common side effects include injection site reactions including redness, pain, and itching. While there is no evidence of harm in pregnancy, such use has not been well studied. It is a small interfering ribonucleic acid (siRNA) that blocks HAO1 messenger ribonucleic acid (mRNA) and thus the creation of hydroxyacid oxidase.

Lumasiran was approved for medical use in Europe and the United States in 2020. In the United States it costs about 60,000 USD for a 94.5 mg vial as of 2022.